Bladder Cancer Combo Treatment Has Shown Promise
A new combination therapy for muscle-invasive bladder cancer may offer patients better survival outcomes.
Updated on Sept. 18, 2026 in Cancer
Live Poll
Should regulatory bodies accelerate approval processes for new combination cancer therapies?
A European Medicines Agency committee has recommended the use of Keytruda combined with Padcev for treating muscle-invasive bladder cancer. This regimen aims to improve outcomes for patients undergoing radical cystectomy.
Why it matters
This recommendation marks a significant potential shift in surgical-adjacent care for bladder cancer, as the combination approach has demonstrated superior clinical trial results compared to standard chemotherapy. These findings provide patients and physicians with a new therapeutic option to discuss for preoperative and postoperative management.
In the Phase 3 KEYNOTE-B15 study, the combination of Keytruda and Padcev demonstrated a 47% reduction in the risk of event-free survival events and a 35% reduction in the risk of death. These results reflect improved pathological responses compared to standard chemotherapy.
The players
European Medicines Agency
The decentralized agency of the European Union responsible for the scientific evaluation, supervision, and safety monitoring of medicines.
U.S. Food and Drug Administration
The U.S. federal agency responsible for protecting public health by ensuring the safety and efficacy of human and veterinary drugs.
The details
The treatment regimen utilizes a subcutaneous version of Keytruda paired with Padcev as a neoadjuvant and adjuvant therapy for patients preparing for radical cystectomy. By combining an immunotherapy with targeted therapy, the regimen is designed to prime the immune system to recognize and attack tumor cells before and after the surgical removal of the bladder. This dual-action approach showed a higher rate of pathologic complete response, meaning no cancer was detectable in the tissue following surgery.
Timeline
June 2026: The European Commission authorized the regimen for cisplatin-ineligible patients.
July 2026: The U.S. Food and Drug Administration cleared Keytruda with Padcev.
September 18, 2026: The recommendation by the European Medicines Agency committee was announced.
Q4 2026: The European Commission is expected to issue a final marketing authorization decision.
Health Landscape
This recommendation follows the Phase 3 KEYNOTE-B15 study, which provided the clinical foundation for incorporating these treatments into surgical planning. It signifies a broader shift toward integrating immunotherapy into standard surgical care pathways for muscle-invasive bladder cancer.
If you or a loved one are facing a diagnosis of muscle-invasive bladder cancer, this development highlights a new potential regimen worth discussing with your oncology team during treatment planning. Ask your physician how emerging neoadjuvant therapies might align with your specific surgical path.
The takeaway
The combination of Keytruda and Padcev has demonstrated significant potential to improve outcomes for patients undergoing bladder cancer surgery. Patients should consult their care team about how evolving neoadjuvant protocols might be integrated into their treatment plan.
What happens next
The European Commission is expected to issue a final marketing authorization decision by the fourth quarter of 2026.
Further reading
For more on the current research and standard care protocols for malignancies, see our Cancer section.
Live Poll
Should regulatory bodies accelerate approval processes for new combination cancer therapies?
